N. Kuribayashi

发表

The Influence of Tofogliflozin on Treatment-Related Quality of Life in Patients with Type 2 Diabetes Mellitus

I. Shimomura, H. Kaneto, T. Matsuoka, 2021, Diabetes Therapy.

Tofogliflozin does not delay progression of carotid atherosclerosis in patients with type 2 diabetes: a prospective, randomized, open-label, parallel-group comparative study

I. Shimomura, H. Kaneto, H. Yokoyama, 2020, Cardiovascular Diabetology.

A randomized controlled trial of two diets enriched with protein or fat in patients with type 2 diabetes treated with dapagliflozin

Mitsutoshi Kato, I. Tatsuno, A. Saiki, 2021, Scientific Reports.

Associations Between Continuous Glucose Monitoring-derived Metrics and Arterial Stiffness in Patients with Type 2 Diabetes

I. Shimomura, H. Watada, Y. Kojima, 2020 .

Glucagon underutilized among type 1 diabetes mellitus patients in Japan.

H. Kitaoka, N. Sakane, M. Furuya, 2013, Diabetes technology & therapeutics.

Correction to: Study Protocol for the Effects of Formula Diet with Dapagliflozin on Metabolic Improvement and Body Composition in Type 2 Diabetes Mellitus

Mitsutoshi Kato, I. Tatsuno, A. Saiki, 2019, Diabetes Therapy.

Study Protocol for the Effects of Formula Diet with Dapagliflozin on Metabolic Improvement and Body Composition in Type 2 Diabetes Mellitus

Mitsutoshi Kato, I. Tatsuno, A. Saiki, 2018, Diabetes Therapy.

Impaired Awareness of Hypoglycemia and Driving Mishaps in Patients with Type 1 Diabetes Mellitus: A Multi-center Survey in Japan

H. Kitaoka, K. Kotani, N. Sakane, 2015 .

Correction to: Effects of periodontal treatment on carotid intima-media thickness in patients with lifestyle-related diseases: Japanese prospective multicentre observational study

S. Takashiba, H. Seino, M. Minabe, 2018, Odontology.

Effects of periodontal treatment on carotid intima-media thickness in patients with lifestyle-related diseases: Japanese prospective multicentre observational study

S. Takashiba, H. Seino, M. Minabe, 2017, Odontology.

Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor sitagliptin compared with α‐glucosidase inhibitor in Japanese patients with type 2 diabetes inadequately controlled on sulfonylurea alone (SUCCESS‐2): a multicenter, randomized, open‐label, non‐inferiority trial

A. Kanatsuka, K. Sakurai, M. Takemoto, 2014, Diabetes, obesity & metabolism.

Self-reported rate of eating is significantly associated with body mass index in Japanese patients with type 2 diabetes. Japan Diabetes Clinical Data Management Study Group (JDDM26)

H. Yokoyama, Koichi Iwasaki, H. Sone, 2012, Appetite.

Analysis of the relationship between periodontal disease and atherosclerosis within a local clinical system: a cross-sectional observational pilot study

S. Takashiba, H. Seino, H. Maeda, 2015, Odontology.

Sitagliptin Attenuates the Progression of Carotid Intima-Media Thickening in Insulin-Treated Patients With Type 2 Diabetes: The Sitagliptin Preventive Study of Intima-Media Thickness Evaluation (SPIKE)

I. Shimomura, H. Kaneto, H. Yokoyama, 2016, Diabetes Care.

Low education is associated with poor periodontal status in patients with type 2 diabetes mellitus: A cross‐sectional study

H. Yokoyama, Tatsuo Yamamoto, F. Okuguchi, 2020, Clinical and experimental dental research.

Alogliptin, a Dipeptidyl Peptidase 4 Inhibitor, Prevents the Progression of Carotid Atherosclerosis in Patients With Type 2 Diabetes: The Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A)

I. Shimomura, H. Kaneto, H. Yokoyama, 2015, Diabetes Care.

Rationale, design, and baseline characteristics of a clinical trial for prevention of atherosclerosis in patients with insulin-treated type 2 diabetes mellitus using DPP-4 inhibitor: the Sitagliptin Preventive study of Intima-media thickness Evaluation (SPIKE)

I. Shimomura, H. Kaneto, H. Yokoyama, 2014, Diabetology & Metabolic Syndrome.

Rationale, design, and baseline characteristics of a trial for the prevention of diabetic atherosclerosis using a DPP-4 inhibitor: the Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A).

I. Shimomura, H. Kaneto, H. Yokoyama, 2013, Journal of atherosclerosis and thrombosis.

Relationship between the efficacy of oral antidiabetic drugs and clinical features in type 2 diabetic patients (JDDM38)

Kokichi Tanaka, O. Tomonaga, Y. Kurihara, 2015, Journal of diabetes investigation.

Efficacy and safety of stepwise introduction of insulin lispro mix 50 in Japanese patients with type 2 diabetes inadequately controlled by oral therapy.

E. Nakashima, T. Imaoka, M. Takeuchi, 2013, Endocrine journal.

Fear of hypoglycemia and its determinants in insulin-treated patients with type 2 diabetes mellitus

H. Kitaoka, K. Kotani, N. Sakane, 2015, Journal of diabetes investigation.

Rationale, Design, and Baseline Characteristics of the Utopia Trial for Preventing Diabetic Atherosclerosis Using an SGLT2 Inhibitor: A Prospective, Randomized, Open-Label, Parallel-Group Comparative Study

I. Shimomura, H. Kaneto, H. Yokoyama, 2017, Diabetes Therapy.

Effect of tofogliflozin on arterial stiffness in patients with type 2 diabetes: prespecified sub-analysis of the prospective, randomized, open-label, parallel-group comparative UTOPIA trial

I. Shimomura, H. Kaneto, H. Yokoyama, 2021, Cardiovascular Diabetology.

Associations between continuous glucose monitoring-derived metrics and arterial stiffness in Japanese patients with type 2 diabetes

I. Shimomura, H. Watada, Y. Kojima, 2021, Cardiovascular Diabetology.

Impaired Awareness of Hypoglycemia in Insulin-Treated Patients with Type 2 Diabetes

H. Kitaoka, K. Kotani, N. Sakane, 2014 .

Applications of physical performance measures to routine diabetes care for frailty prevention concept: fundamental data with grip strength, gait speed, timed chair stand speed, standing balance, and knee extension strength

H. Yokoyama, H. Sone, M. Yamada, 2020, BMJ open diabetes research & care.

Relationship between frequency of hypoglycemic episodes and changes in carotid atherosclerosis in insulin-treated patients with type 2 diabetes mellitus

I. Shimomura, H. Kaneto, H. Watada, 2017, Scientific Reports.

Tofogliflozin long-term effects on atherosclerosis progression and major clinical parameters in patients with type 2 diabetes mellitus lacking a history of cardiovascular disease: a 2-year extension study of the UTOPIA trial

I. Shimomura, H. Kaneto, T. Matsuoka, 2023, Cardiovascular Diabetology.

Impact of having one cardiovascular risk factor on other cardiovascular risk factor levels in adolescents.

M. Shinomiya, Hideto Takahashi, F. Ichida, 2010, Journal of atherosclerosis and thrombosis.

Association of urinary albumin excretion with periodontal parameters in patients with type 2 diabetes mellitus: a cross-sectional study

H. Yokoyama, Tatsuo Yamamoto, F. Okuguchi, 2019, Diabetology International.

Visceral fat accumulation in Japanese high school students and related atherosclerotic risk factors.

M. Shinomiya, Hideto Takahashi, Y. Miyashita, 2010, Journal of atherosclerosis and thrombosis.

Observational 6-Month Open-Label Study of Japanese Type 2 Diabetes Patients Switching from NPH Insulin to Insulin Detemir in Basal—Bolus Regimen: 23rd Article of the Japan Diabetes Clinical Data Management Study Group (JDDM23)

O. Tomonaga, H. Yokoyama, N. Abe, 2012, The Journal of international medical research.

Albuminuria, C-reactive protein, and socioeconomic factors are associated with periodontal status in subjects with type 2 diabetes

H. Yokoyama, Tatsuo Yamamoto, M. Minabe, 2018, Diabetology International.

Efficacy and safety of ipragliflozin and metformin for visceral fat reduction in patients with type 2 diabetes receiving treatment with dipeptidyl peptidase-4 inhibitors in Japan: a study protocol for a prospective, multicentre, blinded-endpoint phase IV randomised controlled trial (PRIME-V study)

I. Tatsuno, K. Yokote, M. Takemoto, 2017, BMJ Open.

Long-term efficacy and safety of early alogliptin initiation in subjects with type 2 diabetes: an extension of the SPEAD-A study

I. Shimomura, H. Kaneto, T. Yasuda, 2023, Scientific reports.